Tag Archives:
Oryzon Nominates Bispecific LSD1/MAOB Inhibitor as Drug Candidate to Enter Preclinical Development in Huntington
Barcelona, Spain (PRWEB) February 05, 2012 ORYZON announced today that it is entering preclinical development with its first drug candidate, a first-in-class bispecific Lysine Specific Demethylase 1 (LSD1) and Monoamine oxidase B (MAO-B) inhibitor for the treatment of Huntington disease … Continue reading
Posted in Mao
Tagged , Bispecific, Candidate, development, disease, Drug, Enter, Inhibitor, LSD1/MAOB, Nominates, Oryzon, Preclinical
Leave a comment